.
| PAS | PSRM | PDA | PN | BA | MAN | PCRM | |||
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 – 2026-09-11 | ATES Research & Consulting / IPP | 41 0% | 17 0% | 13 1% | 8 7% | — | 4 6% | 6 8% | (8 8%) |
| 2026-06-01 – 2026-06-14 | IMAS | 38 0% | 19 9% | 13 6% | 7 2% | — | 4 4% | 5 9% | (11 0%) |
| 2026-05-27 – 2026-06-08 | ATES Research & Consulting | 47 9% | 13 4% | 10 0% | 6 8% | — | 4 7% | 4 1% | (13 1%) |
| 2026-05 | iData | 47 1% | 18 7% | 9 0% | 5 8% | — | 4 9% | 2 0% | (12 5%) |
| 2026-03 | iData | 48 2% | 21 1% | 5 1% | 7 2% | — | 7 3% | 2 5% | (8 6%) |
| 2026-02 | IMAS | 40 8% | 19 6% | 9 9% | 7 7% | 8 9% | — | 5 2% | (7 9%) |
| 2025-12-11 – 2025-12-18 | iData | 46 9% | 21 6% | 7 2% | 7 6% | — | 5 3% | 3 5% | (8 0%) |
| 2025-11-18 – 2025-12-04 | IMAS | 43 0% | 18 5% | 8 6% | 8 7% | 8 6% | — | 5 2% | (7 4%) |
| 2025-09-12 – 2025-09-22 | CBS Research / IPP | 49 5% 56 i |
24 0% 27 i |
3 12% 0 i |
8 8% 10 i |
7 3% 8 i |
— | — | (7 3%) |
| 2025-09-07 – 2025-09-19 | iData | 33 6% 41 i |
33 9% 41 i |
3 1% 0 i |
7 4% 8 i |
9 8% 11 i |
— | — | (12 2%) |
i
| 105 | 105 | 977 | |
| 2021 | 16 | 16 | 116 |
| 2022 | 23 | 23 | 180 |
| 2023 | 21 | 21 | 207 |
| 2024 | 20 | 20 | 190 |
| 2025 | 19 | 19 | 208 |
| 2026 | 6 | 6 | 76 |